Abstract:Hand, foot, and mouth disease (HFMD) is a global health concern. Family Picornaviridae members, particularly enterovirus A71 (EVA71) and coxsackievirus A16 (CVA16), are the primary etiological agents of HFMD; however, a third enterovirus A species, CVA6, has been recently associated with epidemic outbreaks. Study of the pathogenesis of CVA6 infection and development of antivirals and vaccines are hindered by a lack of appropriate animal models. We have developed and characterized a murine model of CVA6 infection that was employed to evaluate the antiviral activities of different drugs and the protective efficacies of CVA6-inactivated vaccines. Neonatal mice were susceptible to CVA6 infection via intramuscular inoculation, and the susceptibility of mice to CVA6 infection was age and dose dependent. Five-day-old mice infected with 105.5 50% tissue culture infective doses of the CVA6 WF057R strain consistently exhibited clinical signs, including reduced mobility, lower weight gain, and quadriplegia with significant pathology in the brain, hind limb skeletal muscles, and lungs of the infected mice in the moribund state. Immunohistochemical analysis and quantitative reverse transcription-PCR (qRT-PCR) analyses showed high viral loads (11 log10/mg) in skeletal muscle, and elevated levels of interleukin-6 (IL-6; >2,000 pg/ml) were associated with severe viral pneumonia and encephalitis. Ribavirin and gamma interferon administered prophylactically diminished CVA6-associated pathology in vivo, and treatment with IL-6 accelerated the death of neonatal mice. Both specific anti-CVA6 serum and maternal antibody play important roles in controlling CVA6 infection and viral replication. Collectively, these findings indicate that this neonatal murine model will be invaluable in future studies to develop CVA6-specific antivirals and vaccines.IMPORTANCE Although coxsackievirus A6 (CVA6) infections are commonly mild and self-limiting, a small proportion of children may have serious complications, such as encephalitis, acute flaccid paralysis, and neurorespiratory syndrome, leading to fatalities. We have established a mouse model of CVA6 infection by inoculation of neonatal mice with a CVA6 clinical isolate that produced consistent pathological outcomes. Here, using this model of CVA6 infection, we found that high levels of IL-6 were associated with severe viral pneumonia and encephalitis, as in an evaluation of antiviral efficacy in vivo, IL-6 had no protective effect and instead accelerated death in neonatal mice. We demonstrated that, as antiviral drugs, both gamma interferon and ribavirin played important protective roles in the early stages of infection, with increased survival in treated neonatal mice challenged with CVA6. Moreover, active and passive immunization with the inactivated vaccines and anti-CVA6 serum also protected mice against homologous challenge infections.

A murine model of coxsackievirus A16 infection for anti-viral evaluation

Protection from Lethal Challenge in a Neonatal Mouse Model by Circulating Recombinant Form Coxsackievirus A16 Vaccine Candidates

A Neonatal Mouse Model for the Evaluation of Antibodies and Vaccines Against Coxsackievirus A6.

A neonatal mouse model of coxsackievirus A10 infection for anti-viral evaluation.

A Neonatal Murine Model of Coxsackievirus A6 Infection for Evaluation of Antiviral and Vaccine Efficacy

Phenotypic and Genomic Characterization of Human Coxsackievirus A16 Strains with Distinct Virulence in Mice

A mouse-adapted CVA6 strain exhibits neurotropism and triggers systemic manifestations in a novel murine model

A potential therapeutic neutralization monoclonal antibody specifically against multi-coxsackievirus A16 strains challenge.

A mouse model and pathogenesis study for CVA19 first isolated from hand, foot, and mouth disease

Proliferation characteristics of coxsackievirus A10 in mice and immune protection ability of experimental inactivated vaccine

Development of A Neonatal Mouse Model for Coxsackievirus B1 Antiviral Evaluation

VP1 Sequence Determination and Phylogenetic Analysis of Coxsackievirus A16 Strains

Inactivated Coxsackievirus A10 Experimental Vaccines Protect Mice Against Lethal Viral Challenge

In Vitro Characterization of Neutralizing Hen Antibodies to Coxsackievirus A16

Pathogenicity and landscape of differential gene expression in mice orally infected with clinical coxsackievirus A6 (CA6)

Construction and Characterization of an Infectious Clone of Coxsackievirus A6 That Showed High Virulence in Neonatal Mice

Amino acid substitutions in VP2, VP1, and 2C attenuate a Coxsackievirus A16 in mice

The Development and Characterization of a Stable Coxsackievirus A16 Infectious Clone with Nanoluc Reporter Gene

Establishment of a Rhesus Macaque Model for Coxsackievirus A6 Infection: Pilot Study to Evaluate Infection Initiated Through the Respiratory or Digestive Track

Coxsackievirus-Induced Acute Neonatal Central Nervous System Disease Model

Investigating the virulence of coxsackievirus B6 strains and antiviral treatments in a neonatal murine model